Business Context and Reporting Period
Pasithea Therapeutics Corp. filed a Form 8-K dated December 20, 2021, reporting executive compensation arrangements for Chief Executive Officer Tiago Reis Marques. The new employment agreement is effective January 1, 2022.
Material Compensation Terms
- Base salary: $450,000 annually.
- Sign-on bonus: $100,000, payable in a lump sum after January 1, 2022.
- Annual bonus: Eligible for a discretionary bonus of up to 75% of base salary actually received during the applicable year.
- Equity awards: The Board approved 200,000 restricted stock units and options to purchase 200,000 common shares.
- Option exercise price: Equal to the closing price of the Company’s common stock on December 20, 2021.
- Vesting: Both awards vest over three years, with one-third vesting after 12 months and the remainder vesting in equal quarterly installments, subject to continued employment and good standing.
- Benefits: Participation in employee benefit programs, including medical and dental coverage for the executive and eligible dependents, and 21 days of paid vacation.
- Severance: If terminated other than for cause, the executive is entitled to 12 months of base salary, subject to standard conditions, payroll deductions, and execution of a release.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating and financial metrics. It also does not quantify the accounting impact or fair value of the equity awards.
Management Commentary, Risks, and Unusual Items
The agreement defines “cause” broadly to include specified criminal conduct, fraud, breach of loyalty, malfeasance, willful misconduct, negligence, failure to perform material duties, intentional property damage, chronic neglect or absenteeism, policy violations, breach of written agreements, and actions that may adversely affect the Company’s publicity or interests.
The employment agreement and equity awards create future cash compensation, potential bonus obligations, severance exposure, and dilution risk from the RSUs and stock options. The filing states that the full agreement will be filed as an exhibit to the Company’s Form 10-K for the fiscal year ended December 31, 2021.
Important Facts for Investors to Verify
- Confirm the complete employment agreement and any additional definitions, conditions, or termination provisions when filed with the Form 10-K.
- Verify the December 20, 2021 closing share price used as the option exercise price.
- Assess the potential dilution from 200,000 RSUs and options for 200,000 shares.
- Review subsequent filings for changes to the CEO’s employment, compensation, equity awards, or severance arrangements.
- Review the Company’s periodic financial statements separately, as this Form 8-K contains no financial performance or liquidity information.